Shares in the drugmaker took a hit after a case of liver failure in one study participant resulted in regulators putting an immediate pause on further dosing or enrollment in the trials.
Shares in the drugmaker took a hit after a case of liver failure in one study participant resulted in regulators putting an immediate pause on further dosing or enrollment in the trials.